RxDoctor Payments Data

Antoinette Davis, MD

Family Medicine · Lantana, FLNPI 1538196738

Payments from drug & device makers

$1,004in general payments, 2019–2025

Across 15 payments — averaging $66.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$381
  • AbbVie$195
  • Novartis$129
  • Novo Nordisk$100
  • Cook Medical LLC$69
  • Astellas Pharma US Inc$65
  • plus $66 from 2 others

What the payments were for

  • Food & beverage$93994%
  • Education$656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,004 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$37,564
Medicare patients
136
Services billed
416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$82,185
EliquisApixaban73$70,760
OzempicSemaglutide64$66,493
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$46,136
XareltoRivaroxaban38$29,437
MyrbetriqMirabegron27$23,312
JanuviaSitagliptin Phosphate21$19,905
LinzessLinaclotide17$13,016
Breo ElliptaFluticasone/Vilanterol16$9,791
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$6,465
Albuterol Sulfate HfaAlbuterol Sulfate113$4,614
Losartan Potassium291$2,604
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,476
Lidocaine12$2,084
Levothyroxine Sodium195$2,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$100$66,49364 claims
GSKTrelegy Ellipta, Breo Ellipta$381$55,92761 claims
Astellas Pharma US IncMyrbetriq$65$23,31227 claims
AbbVieLinzess$195$13,01617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Lantana

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →